FDA records linked by MedtechLedger show four premarket approval entries tied to Biomet Manufacturing Corp under PMA number P010014, all in product code NRA and the Orthopedic advisory committee. The collection includes one original approval and three 30-day notices decided between September and October 2026. The filing address on these records is Warsaw, Indiana, which is a correspondence address in the FDA data rather than a verified headquarters. The records identify the applicant only; no parent, brand owner or commercial partner is confirmed by these documents. [1][2][3][4]

The original approval and its stated indication

P010014 was approved on 21 April 2004 for the OXFORD(TM) MENISCAL UNICOMPARTMENTAL KNEE SYSTEM, described in the FDA record as Phase 3. The approval statement limits the indication to patients with osteoarthritis or avascular necrosis confined to the medial compartment of the knee, with implantation using bone cement. The generic name is a femorotibial, unicompartmental, semi-constrained, metal/polymer, mobile-bearing prosthesis, classified as class III. The record carries docket number 04M-0200 and a Federal Register notice date of 5 May 2004. [4]

2026 30-day notices for manufacturing changes

Three supplements decided in autumn 2026 are 30-day notices for process or supplier changes. S118, decided 1 September 2026, covers an additional supplier of tantalum balls used in manufacturing Oxford Partial Knee Anatomic Vivacit-E Meniscal Bearings at the Zimmer Inc. facility in Warsaw, Indiana. S119, decided 6 October 2026, covers adding a solvent wash step to final cleaning of femoral and tibial components of the Cementless Oxford Partial Knee System at a Shannon, Ireland facility. S120, decided 26 October 2026, changes in-process inspection frequency for tibial components of the Oxford Partial Knee System at a Shannon, Ireland facility. [1][2][3]

What the filing record does and does not establish

The four linked records comprise one approval and three 30-day notices, and the smaller record sample shows the same split of three OK30 decisions and one APPR. These counts describe the retrieved filings at the snapshot date, not total company sales, total portfolio size or safety performance. The FDA approval page for P010014 notes that the device has supplements and that the description or indication may have changed, so the 2004 statement should be read alongside later filings. No recall records appear in the retrieved sample. [1][2][3][4][7]

Product documentation from the manufacturer

Zimmer Biomet publishes an Oxford Partial Knee product page that references a partial knee brochure, a health economics flyer and a cementless Oxford Partial Knee, and directs readers to separate labeling for full prescribing and risk information. That page is the manufacturer's own material; it does not establish that Biomet Manufacturing Corp is the brand owner or that any corporate relationship exists beyond the FDA applicant name. Details such as headquarters, ownership, customers and commercial availability are not documented in these sources. [9]